Reviewing Boston Scientific Corporation (BSX) & Its Rivals

Boston Scientific Corporation (NYSE: BSX) is one of 82 publicly-traded companies in the “Advanced Medical Equipment & Technology” industry, but how does it weigh in compared to its peers? We will compare Boston Scientific Corporation to similar companies based on the strength of its earnings, profitability, dividends, analyst recommendations, risk, institutional ownership and valuation.

Earnings and Valuation

This table compares Boston Scientific Corporation and its peers revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Boston Scientific Corporation $8.71 billion $2.31 billion 49.69
Boston Scientific Corporation Competitors $2.06 billion $438.96 million -75.15

Boston Scientific Corporation has higher revenue and earnings than its peers. Boston Scientific Corporation is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Risk & Volatility

Boston Scientific Corporation has a beta of 1.09, indicating that its stock price is 9% more volatile than the S&P 500. Comparatively, Boston Scientific Corporation’s peers have a beta of 0.89, indicating that their average stock price is 11% less volatile than the S&P 500.

Insider & Institutional Ownership

90.5% of Boston Scientific Corporation shares are owned by institutional investors. Comparatively, 51.0% of shares of all “Advanced Medical Equipment & Technology” companies are owned by institutional investors. 0.7% of Boston Scientific Corporation shares are owned by company insiders. Comparatively, 18.6% of shares of all “Advanced Medical Equipment & Technology” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.


This table compares Boston Scientific Corporation and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Boston Scientific Corporation 9.04% 23.62% 9.01%
Boston Scientific Corporation Competitors -328.60% -36.03% -12.66%

Analyst Ratings

This is a summary of current ratings and recommmendations for Boston Scientific Corporation and its peers, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Boston Scientific Corporation 0 4 13 0 2.76
Boston Scientific Corporation Competitors 263 1835 3294 105 2.59

Boston Scientific Corporation currently has a consensus target price of $30.96, indicating a potential upside of 7.44%. As a group, “Advanced Medical Equipment & Technology” companies have a potential downside of 7.23%. Given Boston Scientific Corporation’s stronger consensus rating and higher possible upside, equities analysts clearly believe Boston Scientific Corporation is more favorable than its peers.


Boston Scientific Corporation beats its peers on 11 of the 13 factors compared.

About Boston Scientific Corporation

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology. It operates in three segments: Cardiovascular, Rhythm Management and MedSurg. Its Cardiovascular segment consists of Interventional Cardiology and Peripheral Interventions businesses. Rhythm Management consists of Cardiac Rhythm Management and Electrophysiology businesses. MedSurg consists of Endoscopy, Urology and Pelvic Health, and Neuromodulation businesses. Its Interventional Cardiology product offerings include balloon catheters, rotational atherectomy systems, guide wires, guide catheters and embolic protection devices and diagnostic catheters used in percutaneous transluminal coronary angioplasty (PTCA) procedures.

Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with's FREE daily email newsletter.

Leave a Reply